Xencor, Inc Loss Contingency, New Claims Filed, Number
Xencor, Inc (XNCR) reported Loss Contingency, New Claims Filed, Number of 2 item for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-08.
Discontinued › Notes › Commitment and Contingencies › Loss Contingency
us-gaap:LossContingencyNewClaimsFiledNumber · last filed 2017-11-08
- Xencor, Inc loss contingency, new claims filed, number for the quarter ending 2017-03-31 was 2.00 item.
| Period end | Loss Contingency, New Claims Filed, Number 3 month | Loss Contingency, New Claims Filed, Number 6 month | Loss Contingency, New Claims Filed, Number 9 month |
|---|---|---|---|
| 2017-09-30 | 2.00 item 10-Q · filed 2017-11-08 | ||
| 2017-06-30 | 2.00 item 10-Q · filed 2017-08-07 | ||
| 2017-03-31 | 2.00 item 10-Q · filed 2017-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |